Switzerland: A recent study published in JAMA Neurology has highlighted key factors influencing the recurrence of ...

Notably, microglia spatially associated with amyloid plaques exhibited increased expression of TREM2 and ApoE compared to ...

Because higher risk of ARIA events has been seen in people with a genetic variant known as APOE4, people with underlying cerebral amyloid angiopathy, and people who take anticoagulants ...

Alnylam Pharmaceuticals ALNY focuses on developing novel therapeutics based on RNAi technology. The company’s pipeline of ...

which is developing ALN-APP in collaboration with Regeneron for both Alzheimer’s and related condition cerebral amyloid angiopathy (CAA), which can cause haemorrhaging in the brain. Eisai and ...

Cerebral amyloid angiopathy (CAA) is driven by vascular Aβ (amyloid‐beta) deposition, which can be detected as reduced Aβ species in cerebrospinal fluid (CSF). We sought to identify relationships ...

The following is a summary of “Validation of the Boston Criteria Version 2.0 for Cerebral Amyloid Angiopathy in Patients Presenting With Intracerebral Hemorrhage,” published in the March 2025 issue of ...

auckland.ac.nz Cerebral amyloid angiopathy related inflammation (CAA-I), previously described under various names, is a treatable encephalopathy usually occurring in older adults. Here, three patients ...

Similarly, accumulation of Aβ aggregates in the cerebral blood vessels in patients with cerebral amyloid angiopathy (CAA) represents a significant risk factor for stroke and AD. PET imaging agents ...

Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer’s disease; and ALN-HTT02 that is in phase I clinical trial for Huntington’s ...